このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Organogenesis Holdings マネジメント

マネジメント基準チェック /24

Organogenesis Holdings'の CEO はGary Gillheeneyで、 Jan2014年に任命され、の在任期間は 10.42年です。の年間総報酬は$ 6.24Mで、 14.6%給与と85.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.63%を直接所有しており、その価値は€ 2.01M 。経営陣と取締役会の平均在任期間はそれぞれ6.8年と3.6年です。

主要情報

Gary Gillheeney

最高経営責任者

US$6.2m

報酬総額

CEO給与比率	14.6%
CEO在任期間	10.7yrs
CEOの所有権	0.6%
経営陣の平均在職期間	7yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Organogenesis Holdings の収益と比較して、Gary Gillheeney の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	US$6m
Dec 31 2023	US$6m	US$909k	US$5m
Sep 30 2023	n/a	n/a	US$13m
Jun 30 2023	n/a	n/a	US$10m
Mar 31 2023	n/a	n/a	US$13m
Dec 31 2022	US$6m	US$883k	US$16m
Sep 30 2022	n/a	n/a	US$59m
Jun 30 2022	n/a	n/a	US$71m
Mar 31 2022	n/a	n/a	US$83m
Dec 31 2021	US$4m	US$835k	US$94m
Sep 30 2021	n/a	n/a	US$62m
Jun 30 2021	n/a	n/a	US$69m
Mar 31 2021	n/a	n/a	US$43m
Dec 31 2020	US$3m	US$823k	US$17m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	n/a	n/a	-US$37m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$1m	US$819k	-US$39m
Sep 30 2019	n/a	n/a	-US$46m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$58m
Dec 31 2018	US$3m	US$798k	-US$65m
Sep 30 2018	n/a	n/a	-US$60m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$32m
Dec 31 2017	US$1m	US$780k	-US$9m

報酬と市場: Garyの総報酬 ($USD 6.24M ) は、 German市場 ($USD 1.05M ) の同規模の企業の平均を上回っています。

報酬と収益: Garyの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Gary Gillheeney (69 yo)

10.7yrs

在職期間

US$6,244,671

報酬

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Gary Gillheeney	President	10.7yrs	US$6.24m	0.63% $ 2.2m
David Francisco	Chief Financial Officer	3.6yrs	US$1.63m	0.048% $ 165.3k
Patrick Bilbo	Chief Operating Officer	7yrs	US$2.16m	0.26% $ 898.3k
Lori Freedman	Chief Administrative & Legal Officer	7.7yrs	US$1.99m	0.063% $ 217.2k
Brian Grow	Chief Commercial Officer	7yrs	US$1.92m	0.078% $ 268.7k
William Kolb	Secretary	no data	データなし	データなし
Robert Cavorsi	Vice President of Strategy	3.7yrs	データなし	0.11% $ 361.7k

7.0yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: 2PQの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Gary Gillheeney	President	5.8yrs	US$6.24m	0.63% $ 2.2m
Glenn Nussdorf	Director	21.7yrs	データなし	11.29% $ 38.7m
Alan Ades	Director	21.7yrs	データなし	11.5% $ 39.5m
Arthur Leibowitz	Lead Independent Director	5.8yrs	US$291.46k	0.10% $ 353.5k
Robert Ades	Director	3.8yrs	データなし	データなし
Jon Giacomin	Independent Director	3.3yrs	US$265.00k	0.068% $ 232.5k
Michele Korfin	Independent Director	2.3yrs	US$226.98k	0.068% $ 232.0k
Prathyusha Duraibabu	Independent Director	2.8yrs	US$240.00k	0.071% $ 242.9k
David Erani	Director	3.8yrs	データなし	データなし
Michael Driscoll	Independent Director	2.6yrs	US$230.52k	データなし
Gilberto Quintero	Independent Director	2.3yrs	US$226.98k	0.068% $ 232.0k

3.8yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: 2PQの取締役会は経験豊富であると考えられます ( 3.6年の平均在任期間)。

Organogenesis Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Insider recently sold €70k worth of stock

High number of new directors

Insider recently sold €94k worth of stock

High number of new directors

Insider recently sold €860k worth of stock

Recent updates

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.04 profit in 2Q 2023)

Organogenesis Holdings Inc. Shares Renu Program Update

Investor sentiment deteriorates as stock falls 18%

Organogenesis Holdings Inc. to Report Q2, 2024 Results on Aug 08, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 28%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.023 loss in 1Q 2023)

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Organogenesis Holdings Inc. to Report Q1, 2024 Results on May 09, 2024

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Investor sentiment deteriorates as stock falls 18%

New minor risk - Earnings quality

Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024

Full year 2023 earnings released: EPS: US$0.038 (vs US$0.12 in FY 2022)

Organogenesis Holdings Inc. to Report Q4, 2023 Results on Feb 29, 2024

Insider recently sold €70k worth of stock

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 17%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings released: EPS: US$0.024 (vs US$0.002 in 3Q 2022)

High number of new directors

Organogenesis Holdings Inc. to Report Q3, 2023 Results on Nov 09, 2023

Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023

Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.067 in 2Q 2022)

Investor sentiment deteriorates as stock falls 19%

Investor sentiment improves as stock rises 23%

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 47%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.023 loss per share (vs US$0.001 profit in 1Q 2022)

Insider recently sold €94k worth of stock

Investor sentiment deteriorates as stock falls 21%

Full year 2022 earnings released: EPS: US$0.12 (vs US$0.73 in FY 2021)

Investor sentiment deteriorates as stock falls 18%

Organogenesis Holdings Inc. to Report Q4, 2022 Results on Mar 01, 2023

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.098 in 3Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Organogenesis Holdings Inc. to Report Q3, 2022 Results on Nov 09, 2022

Investor sentiment deteriorated over the past week

Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution

Second quarter 2022 earnings released: EPS: US$0.067 (vs US$0.16 in 2Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Organogenesis Holdings Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insider recently sold €860k worth of stock

Insider recently bought €58k worth of stock

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

First quarter 2022 earnings released: EPS: US$0.001 (vs US$0.078 in 1Q 2021)

Organogenesis Holdings Inc. Announces Board Changes

High number of new directors

Organogenesis Holdings Inc., Annual General Meeting, Jun 23, 2022

Organogenesis Holdings Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Now 21% undervalued after recent price drop

Organogenesis Appoints Michael J. Driscoll to Board of Directors

Organogenesis Holdings Inc. to Report Q4, 2021 Results on Mar 01, 2022

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Organogenesis Holdings Inc. Investors

Pomerantz LLP Files Class Action Lawsuit Against Organogenesis Holdings Inc

Director recently bought €219k worth of stock

Third quarter 2021 earnings released: EPS US$0.098 (vs US$0.20 in 3Q 2020)

マネジメント基準チェック /24